Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596671 · ClinicalTrials.gov registry record · NA
BlueWind RENOVA iStim™ System for the Treatment of OAB
A NA study, sponsored by BlueWind Medical.
- Completed
- Registry status
- NA
- Development phase
- 282
- Enrollment target
NCT03596671: Completed NA study, sponsored by BlueWind Medical.
NCT03596671 is a NA study that has completed, run by BlueWind Medical. The registered enrollment target is 282 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03596671, a NA study, has completed, sponsored by BlueWind Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 282 participants
- Enrollment target
Study Summary
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder.
Primary Outcome
Proportion of responders at 6 months post system activation as demonstrated by ≥50% improvement in average number of urgency related incontinence episodes, measured by 7-day Patient Voiding Diary.
Interventions
- DEVICE RENOVA iStim™ System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2019-06-12 |
| Est. Completion | 2025-01-24 |
| Phase | NA |
What the finished NCT03596671 record still lists
NCT03596671 is an interventional study that assigns participants to a tested intervention. The registered 282 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which RENOVA iStim™ System is the first listed.
NCT03596671 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03596671 about?
NCT03596671 is a clinical study titled "BlueWind RENOVA iStim™ System for the Treatment of OAB". The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder.
What is the current status of trial NCT03596671?
This trial is currently completed. It is a NA study. The enrollment target is 282 participants. The study started on 2019-06-12. Estimated completion is 2025-01-24.
What interventions are being tested in trial NCT03596671?
The interventions under investigation include: RENOVA iStim™ System (DEVICE).
Who is sponsoring clinical trial NCT03596671?
This trial is sponsored by BlueWind Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03596671's enrollment target sits among peer trials
282 379th of 2000 higher than 1,621 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
- NCT05101070 · 282 participants · Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- NCT06276491 · 282 participants · Phase 1
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI